Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models. [PDF]
Eken JA +10 more
europepmc +1 more source
Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India. [PDF]
Pradhan A, Panchal HP.
europepmc +1 more source
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma. [PDF]
Smith SD +12 more
europepmc +1 more source
Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Management. [PDF]
Tedeschi A +17 more
europepmc +1 more source
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update. [PDF]
McKeague S +27 more
europepmc +1 more source
Bruton Tyrosine Kinase Inhibitor-Associated Pericardial Events by Agent and Generation.
Serra VSB +16 more
europepmc +1 more source
Pirtobrutinib for the Treatment of Therapy-Resistant Chronic Lymphatic Leukemia With CNS Localization. [PDF]
Roerink ME +3 more
europepmc +1 more source
Treatment of Cold Agglutinin Syndrome Secondary to Chronic Lymphocytic Leukemia With Sutimlimab and Obinutuzumab-Venetoclax. [PDF]
Lap CJ, Broome CM.
europepmc +1 more source

